Alpha DNA Investment Management LLC Purchases Shares of 12,843 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Alpha DNA Investment Management LLC purchased a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 12,843 shares of the company’s stock, valued at approximately $411,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Horizon Advisors Inc. raised its position in shares of SpringWorks Therapeutics by 47.9% in the 2nd quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after acquiring an additional 383 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of SpringWorks Therapeutics by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after acquiring an additional 474 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of SpringWorks Therapeutics in the 2nd quarter worth approximately $123,000. Quarry LP raised its position in shares of SpringWorks Therapeutics by 56.3% in the 2nd quarter. Quarry LP now owns 5,000 shares of the company’s stock worth $188,000 after acquiring an additional 1,800 shares in the last quarter. Finally, Commerce Bank bought a new position in shares of SpringWorks Therapeutics in the 3rd quarter worth approximately $207,000.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. HC Wainwright reduced their price objective on SpringWorks Therapeutics from $76.00 to $74.00 and set a “buy” rating for the company in a research report on Tuesday, November 12th. Evercore ISI assumed coverage on SpringWorks Therapeutics in a research report on Wednesday, November 20th. They set an “outperform” rating and a $60.00 price objective for the company. JPMorgan Chase & Co. raised their price objective on SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $77.00 price objective on shares of SpringWorks Therapeutics in a research report on Monday, November 18th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SpringWorks Therapeutics currently has an average rating of “Buy” and a consensus target price of $67.00.

SpringWorks Therapeutics Stock Performance

SWTX stock opened at $39.02 on Monday. SpringWorks Therapeutics, Inc. has a 1 year low of $20.19 and a 1 year high of $53.92. The stock’s fifty day moving average price is $32.60 and its 200-day moving average price is $36.74.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.03. The firm had revenue of $49.10 million for the quarter, compared to the consensus estimate of $53.28 million. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The company’s revenue for the quarter was up 4810.0% on a year-over-year basis. During the same period last year, the business posted ($1.27) EPS. On average, sell-side analysts expect that SpringWorks Therapeutics, Inc. will post -3.12 EPS for the current year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.